TY - JOUR
T1 - Emerging Nano-/Microapproaches for Cancer Immunotherapy
AU - Mi, Yu
AU - Hagan, C. Tilden
AU - Vincent, Benjamin G.
AU - Wang, Andrew Z.
N1 - Funding Information:
The authors would like to thank our funding sources. This work is supported by funding from the National Institutes of Health/National Cancer InstituteU54CA198999, R01 CA178748 and Department of Defense Congressionally Directed Medical Research Programs-Peer Reviewed Cancer Research Program Idea AwardCA150391. B.V. is supported by funding from the UNC University Cancer Research Fund, a Susan G. Komen Foundation Career Catalyst Research Award, and UNC CCNE Pilot Grant.
Funding Information:
The authors would like to thank our funding sources. This work is supported by funding from the National Institutes of Health/National Cancer Institute U54CA198999, R01 CA178748 and Department of Defense Congressionally Directed Medical Research Programs-Peer Reviewed Cancer Research Program Idea Award CA150391. B.V. is supported by funding from the UNC University Cancer Research Fund, a Susan G. Komen Foundation Career Catalyst Research Award, and UNC CCNE Pilot Grant.
Publisher Copyright:
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/3/20
Y1 - 2019/3/20
N2 - Cancer immunotherapy has achieved remarkable clinical efficacy through recent advances such as chimeric antigen receptor-T cell (CAR-T) therapy, immune checkpoint blockade (ICB) therapy, and neoantigen vaccines. However, application of immunotherapy in a clinical setting has been limited by low durable response rates and immune-related adverse events. The rapid development of nano-/microtechnologies in the past decade provides potential strategies to improve cancer immunotherapy. Advances of nano-/microparticles such as virus-like size, high surface to volume ratio, and modifiable surfaces for precise targeting of specific cell types can be exploited in the design of cancer vaccines and delivery of immunomodulators. Here, the emerging nano-/microapproaches in the field of cancer vaccines, immune checkpoint blockade, and adoptive or indirect immunotherapies are summarized. How nano-/microparticles improve the efficacy of these therapies, relevant immunological mechanisms, and how nano-/microparticle methods are able to accelerate the clinical translation of cancer immunotherapy are explored.
AB - Cancer immunotherapy has achieved remarkable clinical efficacy through recent advances such as chimeric antigen receptor-T cell (CAR-T) therapy, immune checkpoint blockade (ICB) therapy, and neoantigen vaccines. However, application of immunotherapy in a clinical setting has been limited by low durable response rates and immune-related adverse events. The rapid development of nano-/microtechnologies in the past decade provides potential strategies to improve cancer immunotherapy. Advances of nano-/microparticles such as virus-like size, high surface to volume ratio, and modifiable surfaces for precise targeting of specific cell types can be exploited in the design of cancer vaccines and delivery of immunomodulators. Here, the emerging nano-/microapproaches in the field of cancer vaccines, immune checkpoint blockade, and adoptive or indirect immunotherapies are summarized. How nano-/microparticles improve the efficacy of these therapies, relevant immunological mechanisms, and how nano-/microparticle methods are able to accelerate the clinical translation of cancer immunotherapy are explored.
KW - adoptive immunotherapy
KW - cancer immunotherapy
KW - cancer vaccines
KW - checkpoint blockades
KW - combination immunotherapy
KW - nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85059959219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059959219&partnerID=8YFLogxK
U2 - 10.1002/advs.201801847
DO - 10.1002/advs.201801847
M3 - Review article
C2 - 30937265
AN - SCOPUS:85059959219
SN - 2198-3844
VL - 6
JO - Advanced Science
JF - Advanced Science
IS - 6
M1 - 1801847
ER -